Evaluation of Efficacy and Safety of a Combination Containing Myo-inositol, D-chiro-inositol, Alpha-lactalbumin, Zinc and Extract of Gymnema Sylvestre in Subjects Diabetic Patients. (MYDIAGYM)
Randomized, Controlled, Open-label Study to Evaluate the Efficacy and Safety of a Combination Containing Myo-inositol, D-chiro-inositol, Alpha-lactalbumin, Zinc and Extract of Gymnema Sylvestre in Subjects With Type 2 Mellitus Diabetes.
Sponsor: Lo.Li.Pharma s.r.l
Listed as NCT04745780, this NA trial focuses on Type 2 Diabetes and remains completed. Sponsored by Lo.Li.Pharma s.r.l, it has been updated 6 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Jul 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Jul 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2023 — Jul 2024 [monthly]
Completed NA
Status: Recruiting → Completed
-
May 2022 — Jan 2023 [monthly]
Recruiting NA
▶ Show 1 earlier version
-
Mar 2021 — May 2022 [monthly]
Recruiting NA
First recorded
Feb 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Lo.Li.Pharma s.r.l
For direct contact, visit the study record on ClinicalTrials.gov .